Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 29, 2025 in Petco Health and Wellness Company, Inc. Lawsuit
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/petco-lawsuit-submission-form?prid=158431&wire=56
WOOF investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: (i) Petco's pandemic-related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high-grade pet food; (ii) accordingly, the strength of Petco's differentiated product strategy was overstated; (iii) defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco's comparable sales metric; (iv) accordingly, defendants overstated Petco's ability to deliver sustainable, profitable growth; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Petco during the relevant time frame, you have until August 29, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Petco. Listen now and find out if you are eligible to join the lawsuit.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
This Quantum Computing Company Just Unlocked a New AI Breakthrough
Key Points Rigetti has achieved a significant error rate reduction with a 36-qubit system. This could pave the way for quantum computers with more qubits that can be used for AI. There's still a long way to go, though -- and Rigetti's stock remains a speculative bet. 10 stocks we like better than Rigetti Computing › What are currently the two hottest technologies? Artificial intelligence (AI) deserves a spot at the top, for sure. There's a strong case for quantum computing taking second place. Not so coincidentally, these two technologies are joined at the hip in some ways. When a key milestone is achieved in quantum computing, it can translate to a step forward for AI, too. That appears to be the case with a recent announcement from Rigetti Computing (NASDAQ: RGTI). This quantum computing company arguably just unlocked a new AI breakthrough. Rigetti's breakthrough On July 16, 2025, Rigetti Computing revealed that it had achieved 99.5% median 2-qubit gate fidelity with its modular 36-qubit quantum computing system. This reflected a halving of the company's best 2-qubit gate error rate with its 84-qubit Ankaa-3 system. If all that sounds like techno-gobbledygook to you, you're not alone. Quantum computing is complicated, with jargon that can be confusing. Let's try to make sense of Rigetti's breakthrough. First, qubits (short for "quantum bits") are similar to the binary bits 0 and 1 used in traditional computers. The big difference is that qubits can be 0, 1, or even both simultaneously. Quantum gates are the building blocks of quantum circuits. They're like logic gates used in traditional computers (such as AND, OR, and NOT) to perform operations. What does it mean that Rigetti achieved 99.5% median 2-qubit gate fidelity? When 2 qubits interact in a "gate" operation, the result is correct 99.5% of the time, with an error rate of five in 1,000 operations. The fewer errors, the more useful a quantum computer is. What does improved quantum gate error rates mean for AI? Rigetti didn't mention AI at all in its announcement. However, its quantum computing breakthrough could have important ramifications for AI. Error correction ranks as one of the biggest problems with quantum computers today. Too many errors make a quantum computer useless in practical applications. That's especially the case with AI, which requires multiple iterations and a high degree of precision in its under-the-hood processing. However, lower error rates allow quantum computers to run longer and use more quantum gates before the accumulated errors cause major problems. It also paves the way for quantum computers with more qubits, which will be a must for training and deploying large-scale AI models. We're seeing this with Rigetti already. The company made its breakthrough on a 36-qubit system. However, it plans to release a 100-plus-qubit system that will have 99.5% median 2-qubit gate fidelity before the end of this year. CEO Subodh Kulkarni stated, "By leveraging well-known techniques from the semiconductor industry, we've developed proprietary technology that we believe is critical to enable scaling to higher qubit count systems." Now for a reality check: Five errors in 1,000 operations isn't nearly good enough. The error rate needs to fall to around one in a million for quantum computers to run useful applications. Some more complex applications will need error rates of one in a billion or better. However, Rigetti's achievement is nonetheless an important milestone in getting to these lower error rates. Is Rigetti Computing stock a smart pick to buy now? If you want to know how significant investors viewed Rigetti's breakthrough, just look at its stock chart. The quantum computing company's share price soared after its announcement earlier this month. Over the last three months, Rigetti stock is up close to 80%. Is this quantum computing stock a smart pick to buy now? Not for risk-averse investors. Rigetti remains unprofitable. It also faces stiff competition from both large and small companies scrambling to develop quantum computers. There's no guarantee that Rigetti will be among the winners in quantum computing over the long run. However, aggressive investors who are willing to take on considerable risk might find Rigetti appealing. It's a speculative stock, to be sure. But if Rigetti can continue to make the technological advances needed to build a practical, large-scale quantum computer, it's likely to be a huge winner over the next decade and beyond. Should you invest $1,000 in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
4 hours ago
- Globe and Mail
Wall Street Is Watching This One Metric in Nvidia's Q2 -- Can It Deliver?
Nvidia (NASDAQ: NVDA) recently became the world's first $4 trillion tech titan -- but the second quarter could be the spark for its next mega move. With quantum computing breakthroughs, artificial intelligence (AI) networking dominance, and a stealth China rebound on the horizon, this earnings report might deliver more than Wall Street expects. *Stock prices used were the market prices of July 28, 2025. The video was published on Aug. 2, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Rick Orford
Globe and Mail
8 hours ago
- Globe and Mail
3 Unstoppable Stocks to Buy in August
Key Points Investors have multiple reasons to like AbbVie stock. Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic fibrosis. 10 stocks we like better than AbbVie › The "it" factor. Some stocks have it. Other stocks don't. But the ones that do can be virtually unstoppable. Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and they're all in the healthcare sector. Here's why they picked AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). There are many reasons to buy this stock Prosper Junior Bakiny (AbbVie): It's been a little over two years since AbbVie lost patent exclusivity for its best-selling drug, autoimmune disease medicine Humira. That didn't stop AbbVie, though; it just slowed it down momentarily. The company rebounded nicely and has since returned to top-line growth. AbbVie now owns another one of the top-10 selling therapies in the world, Skyrizi, which targets several immunology conditions. Skyrizi's sales have been growing at an incredibly rapid rate. Together with Rinvoq, AbbVie's immunology lineup has successfully filled the gap left by Humira. That's an important reason to consider the stock: AbbVie's ability to overcome a significant patent cliff speaks volumes about its innovative abilities. Beyond that, AbbVie's lineup is deep. It features older products that continue to make meaningful contributions to its financial results, such as its Botox franchise, and newer products that can help drive top-line growth for a while, like migraine treatment Qulipta. AbbVie's pipeline also looks deep. The company should be able to record consistent clinical and regulatory wins. Lastly, we can't mention AbbVie without pointing out its incredible dividend track record. The company is part of the exclusive group of Dividend Kings, boasting an active streak of 53 consecutive payout increases, which includes the time it spent as a division of its former parent company, Abbott Laboratories. AbbVie's forward yield of 3.5% is much higher than the S&P 500 's average of 1.3%, and its cash payout ratio looks reasonable at 61.8%. In addition to an excellent underlying business, a strong lineup, and a solid pipeline, AbbVie is an outstanding stock for income-seeking investors. Investing in this company could yield superior returns over the long term. Eli Lilly is a top growth stock to own for years David Jagielski (Eli Lilly): A stock that looks unstoppable right now is Eli Lilly. While many investors will focus on its highly successful GLP-1 drugs, Zepbound and Mounjaro, as the main reasons to invest in the business, there's much more behind the company, and why it's a top growth stock. Eli Lilly has a promising Alzheimer's treatment, Kisunla, which regulators approved for use last year. It's still in the early innings of its growth and according to analysts, it could generate up to $5 billion in annual revenue at its peak. Meanwhile, Eli Lilly is still focusing on developing more life-changing treatments for patients. It's planning to invest $4.5 billion into a research and manufacturing facility, which it calls Lilly Medicine Foundry. By utilizing new manufacturing methods to ensure high efficiency, the new center can help the company scale and bring new products to market faster. The company also has vast resources at its disposal, which can help it invest in research and development and potentially acquire promising businesses along the way. In the trailing 12 months, Eli Lilly has generated $11.1 billion in profit on sales totaling $49 billion. The company's terrific margins, strong growth prospects, and commitment to producing new treatments are why this pharmaceutical stock can be among the best investments you can put in your portfolio right now. A big biotech innovator that's targeting new markets Keith Speights (Vertex Pharmaceuticals): To truly be unstoppable, a company can't have competition that could, well, stop it. Vertex Pharmaceuticals has this covered with its cystic fibrosis (CF) franchise. No other drugmaker has approved therapies that treat the underlying cause of CF. The number of companies with experimental CF therapies in late-stage clinical testing that could compete with Vertex totals... zero. Actually, Vertex's biggest rival in treating CF is itself. The company's newest CF therapy, Alyftrek, offers a more convenient once-per-day dosing than its current top-seller, Kaftrio/Trikafta. However, CF isn't the main reason why I like Vertex. My primary interests lie with other indications the biotech innovator is targeting. For example, Vertex won U.S. regulatory approval for Journavx earlier this year. It's the first new class of pain medication in over 20 years. Journavx is safe and effective, with none of the side effects and addictive potential associated with opioids -- because it isn't an opioid. The company's pipeline features promising late-stage programs that could further expand Vertex's market opportunity. Inaxaplin targets APOL1-mediated kidney disease, which affects around 250,000 patients worldwide. Povetacicept holds the potential to treat multiple kidney diseases, with IgA nephropathy first on the list with a patient population of over 1 million. Zimislecel could cure severe type 1 diabetes. At first glance, Vertex might seem to be priced at a premium, with its shares trading at 26.3 times forward earnings. However, the company's growth prospects are so strong that its valuation is attractive. Vertex's price-to-earnings-to-growth (PEG) ratio, based on analysts' five-year earnings growth estimates, is a super-low 0.58. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 David Jagielski has no position in any of the stocks mentioned. Keith Speights has positions in AbbVie and Vertex Pharmaceuticals. Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
